OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
| OABI Stock | USD 3.90 0.12 3.17% |
Under 63% of all OmniAb's traders are looking to take a long position. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that some traders are interested. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
OmniAb, Inc. will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial ma
Read at businesswire.com
 |
OmniAb Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
OmniAb is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
| IPSC | Century Therapeutics | 20.74 | ||||
| ACET | Adicet Bio | 15.63 | ||||
| PASG | Passage Bio | 11.94 | ||||
| GLUE | Monte Rosa | 5.93 | ||||
| ERAS | Erasca | 5.04 | ||||
| BCAB | Bioatla | 4.46 | ||||
| ITOS | Iteos Therapeutics | 4.27 | ||||
| OLMA | Olema Pharmaceuticals | 4.12 | ||||
| CGEM | Cullinan Oncology | 2.51 | ||||
| KROS | Keros Therapeutics | 2.02 | ||||
| LEGN | Legend Biotech | 1.29 | ||||
| IDYA | Ideaya Biosciences | 0.78 | ||||
| PMVP | Pmv Pharmaceuticals | 0.63 | ||||
| VRNA | Verona Pharma | 0.15 | ||||
| EWTX | Edgewise Therapeutics | 0.37 | ||||
| IKNA | Ikena Oncology | 1.17 | ||||
| VOR | Vor Biopharma | 1.25 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |